



## **Mersana Therapeutics to Present at the Leerink Partners 5th Annual Global Healthcare Conference**

February 4, 2016

**CAMBRIDGE, Mass., February 4, 2016** -- Mersana Therapeutics, Inc. today announced that Anna Protopapas, President and Chief Executive Officer, will present at the Leerink Partners 5th Annual Global Healthcare Conference at the Waldorf Astoria in New York City on Wednesday, February 10, 2016, at 8:50 a.m. ET.

### **About Mersana Therapeutics**

Mersana Therapeutics is advancing a proprietary pipeline of targeted oncology therapeutics leveraging its game-changing Fleximer® immunoconjugate technology. Mersana's first product candidate XMT-1522 has the potential to address significant unmet needs and improve patient outcomes in multiple oncology indications. Fleximer-based immunoconjugate molecules have been shown to have superior efficacy, including with targets previously considered not amenable to antibody-drug conjugate approaches. Mersana has collaborations utilizing Fleximer technology with Takeda, Merck KGaA, and Asana BioSciences. For more information, please visit [www.mersana.com](http://www.mersana.com).

###

### **Media Contact**

6 Degrees  
Tony Plohoros  
[tplohoros@6degreespr.com](mailto:tplohoros@6degreespr.com)  
(908) 591-2839

### **Investors Contact**

Stern Investor Relations, Inc.  
Jesse Baumgartner  
[Jesse@sternir.com](mailto:Jesse@sternir.com)  
(212) 362-1200